APP and neoplasm: Our findings demonstrated that diverse immune cell subsets (MDSCs, Tregs, CD4+ or CD8+ T cells, and DCs) across tumor tissues and lymphoid organs were differentially regulated by oAd/APP+DC combination therapy that were suggestive of systemic antitumor immune response.